Why worrisome coronavirus mutations may soon hit their limit

The novel coronavirus that sparked the ongoing COVID-19 pandemic will continue to evolve over time, but it may be running out of the type of worrisome tricks seen in mutations first sequenced in the United Kingdom, Brazil, and South Africa, Dr. Dhruv Khullar writes in The New Yorker.
All three variants are troubling because of a change to the "spike" protein that allows the virus to latch on to humans' ACE-2 receptor and enter human cells more easily, making it more transmissible. And the Brazilian and South African variants carry an additional mutation which diminishes the ability of antibodies to bind to and neutralize the virus, possibly rendering previous infection and vaccines less effective, Khullar writes. There is good news, though — at least in the eyes of Jason McLellan, a structural biologist at the University of Texas at Austin, who believes such mutations may be few and far between going forward.
"There's just not a lot of space for the spike to continue to change in ways that allow it to evade antibodies but still bind to its receptor," McLellan told Khullar. "Substitutions that allow the virus to resist antibodies will probably also decrease its affinity for ACE-2," he continued, adding that because the variants "have independently hit on the same mutations" it's likely "we're already seeing the limits of where the virus can go."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
McLellan expanded on his fairly hopeful outlook, telling Khullar that the virus will indeed keep mutating, but likely into a less lethal version. "This is what we think happened to viruses that cause the common cold," he said. "It probably caused a major illness in the past. Then it evolved to a place where it's less deadly." Read more at The New Yorker.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Entitlements: DOGE goes after Social Security
Feature Elon Musk is pushing false claims about Social Security fraud
By The Week US Published
-
The Week contest: Amazon Bond
Puzzles and Quizzes
By The Week US Published
-
6 grand homes in Boulder
Feature Featuring a mountain-facing balcony in Lower Chautauqua and a clover-shaped home in Flagstaff
By The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published